En el camino para acortar los tratamientos de la tuberculosis: los ensayos clínicos de la Unitat d'Investigació en la Tuberculosi de Barcelona impulsados por los Centres for Disease Control and Prevention

Moreno, Antonio; Sánchez, Francesca; Nelson, Jeanne; Miró, José M.; Caylà, Joan A.; ,

My SciELO

Custom services

Services on Demand

Journal

Article

Indicators

Cited by SciELO
Access statistics

Gaceta Sanitaria

Print version ISSN 0213-9111

Abstract

MORENO, Antonio and GRUPO DE TRABAJO DE LA UITB-TBTC (SITE 31) et al. On the way to shortening tuberculosis treatments: clinical trials of the Unitat d' Investagació en Tuberculosi de Barcelona supported by the Centers for Disease Control and Prevention. Gac Sanit [online]. 2010, vol.24, n.2, pp.171.e1-171.e6. ISSN 0213-9111.

New treatment guidelines are required to improve the tuberculosis control strategies that have been used for 30 years. Seven centers of the Barcelona Tuberculosis Research Unit (BTRU) (Unitat d Investigació en Tuberculosi de Barcelona) are collaborating with the Division of Tuberculosis Elimination of the United States Centers for Disease Control and Prevention in a series of clinical trials on latent tuberculosis infection and tuberculosis disease. BTRU participation began in 2004 with Study 26, an evaluation of the efficacy and tolerability of rifapentine plus isoniazid administered once weekly for 3 months compared with the standard treatment for latent tuberculos isinfection. The BTRU centers together enrolled 246 patients (3% of the total).General enrollment was completed in February, 2008. HIV-infected patient and child enrollment continues. Treatment with 12 doses instead of 270 doses is expected to be a clear success. However, the analysis will be completed in 2010. Study 28 (startedin2006), designed for the treatment of pulmonary tuberculosis, compared standard treatment with an experimental regimen substituting moxifloxacin for isoniazid. BTRU centers together enrolled 15 patients (3.5 % of the total).The provisional results (presented at the 47th Interscience Conferenceon Antimicrobial Agents and Chemotherapy in Chicago, 2007) showed no difference between the sputum conversion rate of each regimen at week 8 of treatment. Study 29 is currently underway,in which rifapentine was introduced in the experimental regimen for active tuberculosis treatment.

Keywords : Tuberculosis; Clinical trials; Treatment; Prevention; Tuberculosis Trials Consortium.

· abstract in Spanish · text in Spanish · Spanish (

pdf )